
    
      Primary Aim: To estimate the antidepressant efficacy of isradipine versus placebo as an
      adjunct to lithium, valproate, and/or other atypical antipsychotics among individuals with
      bipolar I disorder in a nonpsychotic major depressive episode.

      Hypothesis: Isradipine will be superior to placebo in improvement of depressive symptoms
      assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).
    
  